Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Mayo Clinic
Sapience Therapeutics
M.D. Anderson Cancer Center
Hoffmann-La Roche
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
National Cheng-Kung University Hospital
City of Hope Medical Center
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Proton Collaborative Group
Providence Health & Services
Mayo Clinic
Weill Medical College of Cornell University
Washington University School of Medicine
Shandong Cancer Hospital and Institute
BeiGene
Vanderbilt-Ingram Cancer Center
Stanford University
University Hospital Hradec Kralove
University of Wisconsin, Madison
Fred Hutchinson Cancer Center
Ludwig Institute for Cancer Research
Icahn School of Medicine at Mount Sinai
M.D. Anderson Cancer Center
Cancer Trials Ireland
National Cancer Institute (NCI)
Fred Hutchinson Cancer Center
NYU Langone Health
National Cancer Institute (NCI)
University of Texas Southwestern Medical Center
Alliance for Clinical Trials in Oncology
Independent Public Care Health Facility of the Ministry of the Interior and Warmian & Mazurian Oncology Centre
University of Utah
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Stanford University
NYU Langone Health
ChineseAMS
University of Washington
Fred Hutchinson Cancer Center
Eli Lilly and Company
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
OHSU Knight Cancer Institute
Korea Cancer Center Hospital
Clinical Oncology Research Associates